ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?

Sunday at the annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco , the Indianapolis drugmaker unveiled data showing Trulicity had pared down the combined rate of heart attack, stroke and cardiovascular death by 12%. While Trulicity produced numerical benefits in each of those categories, they weren’t statistically significant.